Treatment of Low-Risk Basal Cell Carcinoma

Journal of Investigative Dermatology

Volumn 137, Issue 3, 2017, Pages 539-540

  Kelleners Smeets, Nicole W J ^a,b   Mosterd, Klara ^a,b   Nelemans, Patty J ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT;

BASAL CELL CARCINOMA; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; HUMAN; MEDICAL DECISION MAKING; NOTE; PAIN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SUPERFICIAL CANCER; SKIN TUMOR; TREATMENT OUTCOME;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; HUMANS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 85013933268     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2016.11.021     Document Type: Note

References (8)

1. Bath-Hextall, F.J., Perkins, W., Bong, J., Williams, H.C., Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev, 2007, CD003412.
2. Bath-Hextall, F., Ozolins, M., Armstrong, S.J., Colver, G.B., Perkins, W., Miller, P.S., et al., Surgery versus Imiquimod for Nodular Superficial basal cell carcinoma (SINS) study group. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 15 (2014), 96–105.
3. Fremlin, G.A., Gomez, P., Halpern, J., Are there sufficient numbers of low-risk basal cell carcinomas to justify general practitioners (family physicians) carrying out basal cell carcinoma surgery?. Clin Exp Dermatol 41 (2016), 138–141.
4. Mosterd, K., Arits, A.H.M.M., Nelemans, P.J., Kelleners-Smeets, N.W.J., Aesthetic evaluation after non-invasive treatment for superficial basal cell carcinoma. J Eur Acad Dermatol Venereol 27 (2013), 647–650.
5. Roozeboom, M.H., Arits, A.H., Mosterd, K., Sommer, A., Essers, B.A., de Rooij, M.J., et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. J Invest Dermatol 136 (2016), 1568–1574.
6. Tinelli, M., Ozolins, M., Bath-Hextall, F., Williams, H.C., What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial. BMC Dermatol, 12, 2012, 19.
7. van Rijsingen, M.C., Hanssen, S.C., Groenewoud, J.M., van der Wilt, G.J., Gerritsen, M.J., Referrals by general practitioners for suspicious skin lesions: the urgency of training. Acta Derm Venereol 94 (2014), 138–141.
8. Williams, H.C., Bath-Hextall, F., Ozolins, M., Armstrong, S.J., Colver, G.B., Perkins, W., et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomised controlled trial. J Invest Dermatol 137 (2017), 614–619.